Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00148824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Amendment history

  1. Notable

    Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseases

    Study sites: 0 to 1; Publications: 1 to 2

    Show what changed: Publications
    Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, Katlama C, Yeni P, Morineau P, Delfraissy JF, Chene G, Levy Y; ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007 Nov 30;21(18):2425-34. doi: 10.1097/QA [...]

    Study Identification, Study Status, Sponsor/Collaborators, Contacts/Locations, Referencesv7

  2. Minor

    Study Status

    Re-verified, no change to tracked fields

    v6

  3. Minor

    Trial status: Terminated to Completed

    Study Statusv5

  4. Stopped

    Trial status: Active, Not Recruiting to Terminated

    Completion date: Dec 2005 to Jan 2006

    Study Statusv4

  5. Minor

    2 amendments

    2 re-verifications since 2005-10-19, no change to tracked fields

    v2-v3

  6. Minor

    Study First Submitted

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.
Trial Details
NCT Number NCT00148824
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer
Conditions HIV Infections
Enrollment 212 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov